Nootropics

Nootropics are substances taken with the intention of improving memory, attention, motivation or executive function in people who are not cognitively impaired. The category is defined by user intent rather than by pharmacology, and it spans prescription stimulants, an over-the-counter supplement industry, and compounds sold as research chemicals. The evidence divides sharply: a few agents produce small, replicable effects on laboratory tasks, and most of the market produces none.

§Origins and definition

The Romanian pharmacologist Corneliu Giurgea synthesised piracetam at the Belgian firm UCB in 1964 and coined "nootropic" — from the Greek for mind-turning — around 1972 to name a class of drug he believed acted on higher integrative brain function without the sedation, stimulation or toxicity of existing psychoactive agents.¹ He proposed five criteria: enhancement of learning and memory; protection of learned behaviour against disruption; protection of the brain against physical or chemical injury; improvement of tonic cortical control mechanisms; and an absence of the usual psychotropic side effects.

The criteria have not aged well as a research programme. No compound has been shown to meet all five in humans, and piracetam itself, the drug the definition was built around, has never been approved in the United States and has weak evidence for the indications it is licensed for elsewhere. In practice "nootropic" now denotes a market segment rather than a pharmacological class, and much of what is sold under the label would have failed Giurgea's fifth criterion immediately.

1. 1964
   Piracetam synthesised
   Corneliu Giurgea's team at UCB produces the first racetam while looking for a compound active on the cortex.
2. c. 1972
   The term coined
   Giurgea proposes 'nootropic' and a five-part definition intended to mark out a genuinely new drug class.
3. 1998
   Modafinil approved
   Modafinil is approved in the United States for narcolepsy, and becomes the most-studied off-label wakefulness agent.
4. 2008
   The Nature poll
   An informal reader survey finds about one in five respondents reporting non-medical use of drugs for focus, memory or concentration, and puts the issue on the scientific agenda.
5. 2015
   Systematic reviews
   Reviews of modafinil and of prescription stimulants in healthy people converge on small, task-dependent effects rather than general cognitive gain.
6. 2019–2020
   Adulteration documented
   Analyses of commercial cognitive-enhancement supplements find unapproved drugs present, sometimes at doses exceeding pharmaceutical ranges, and regulators issue warning letters.

§What the evidence supports

Caffeine is the most widely used psychoactive substance in the world and the best-established agent in the category. It reliably improves alertness, vigilance and reaction time, especially under fatigue. A long-standing dispute concerns how much of the benefit in habitual users is restoration from overnight withdrawal rather than enhancement above an unmedicated baseline; the withdrawal-reversal effect is real, though evidence in non-consumers suggests it does not explain the whole effect.

Modafinil is licensed for narcolepsy and shift-work sleep disorder and used off-label for wakefulness. In sleep-deprived people its effects are clear. In rested healthy volunteers, a systematic review by Battleday and Brem found consistent improvement on complex tasks involving attention, executive function and learning, and little or no effect on simple tasks or on mood.² An earlier review by Repantis and colleagues had reached a more cautious conclusion, finding limited evidence for enhancement outside sleep deprivation.³ Both note that longer and more demanding tasks show effects that brief tests miss.

Prescription stimulants — methylphenidate and amphetamine salts — have been studied extensively in healthy adults. A meta-analysis by Ilieva, Hook and Farah found small effects on inhibitory control, working memory and delayed episodic memory, on the order of a fifth to a third of a standard deviation.⁴ Subjective reports of improvement consistently exceed measured performance, which is the finding most relevant to how these drugs are actually used. Effects are larger in low performers than in high performers, an inversion of the usual assumption about who benefits from enhancement.

The size of the effect

The largest replicated cognitive gains from a nootropic in rested healthy adults are comparable to the effect of a night of adequate sleep or of moderate aerobic exercise, both of which are free and have no dependence liability. Any evaluation of the class has to start from that comparison.

§What the evidence does not support

The racetams. Piracetam, aniracetam, oxiracetam and phenylpiracetam are the compounds most closely associated with the word "nootropic". A Cochrane review of piracetam for dementia and cognitive impairment concluded the evidence was insufficient to support its use.⁵ Controlled data in healthy young adults are sparse, small and mostly old. The newer racetams have essentially no published human trials at all.

Herbal and supplement agents. Ginkgo biloba was tested in a large, long randomised prevention trial and did not reduce the incidence of dementia.⁶ Bacopa monnieri, Rhodiola, lion's mane and citicoline have small trials with mixed results and heterogeneous preparations. Effects reported in this literature are rarely distinguishable from expectancy, and the placebo response for a subjectively assessed cognitive outcome is large.

Proprietary blends. Products combining a dozen ingredients at undisclosed doses cannot be evaluated. Where they have been analysed chemically, results have been poor: Cohen and colleagues found several unapproved drugs, including omberacetam, phenibut, vinpocetine, picamilon and aniracetam, present in commercially sold cognitive-enhancement supplements, sometimes at doses above those used pharmaceutically.⁷ Phenibut in particular carries dependence and withdrawal risk that consumers buying a "focus" supplement have no reason to expect.

Regulatory gap

In the United States, Dietary supplements are not reviewed for efficacy before sale, and enforcement is post-market. A compound withdrawn from a supplement after a warning letter can reappear under a different name. Consumers of this market are not protected by the evidence standards that apply to the prescription drugs in the same category.

§Mechanisms and why they are hard to establish

The agents with real effects act on arousal and catecholamine signalling. Caffeine antagonises adenosine receptors; stimulants increase synaptic dopamine and noradrenaline; modafinil's action is less well characterised but involves dopamine transporter inhibition among other effects. None of these mechanisms is specific to cognition. They shift arousal and motivation, and cognitive performance changes as a consequence, which is why effects follow an inverted-U with dose and baseline state.

Wakefulness agents add a further complication: suppressing sleepiness is not the same as reducing the need for sleep, and the debt continues to accumulate while the drug masks it, an asymmetry examined in Engineered sleep reduction. That structure has three consequences. Gains at one point on the curve are losses at another, so a drug that helps a tired person can impair a rested one. Improvement on one function often costs another: stimulants can narrow attention in a way that helps rote tasks and hurts creative or divergent ones. And a drug that raises confidence more than performance will be judged effective by the person taking it regardless of what it does. Careful studies of putative cognitive enhancers therefore separate objective measures from self-report, and the two frequently diverge.

§Use, ethics and policy

Non-medical stimulant use is concentrated in academic and competitive settings, where the pressure is positional. The ethical structure is the one described in Enhancement arms race: where enough peers use a drug, declining ceases to be a neutral choice. Bioethicists writing in support of open access — the position developed in Bioethics of enhancement and defended by Julian Savulescu among others, and grounded in the autonomy claim of Morphological freedom — argue that a safe and effective cognitive drug should be treated like caffeine. Critics reply that the conditional has not been satisfied, since none of the drugs in question have been assessed for long-term safety in healthy users, and that prescription diversion is not a considered policy. The unregulated end of the market overlaps with the self-experimentation described in Biohacking and grinders, where dosing decisions are made from forum consensus.

Sport treats the question differently. Stimulants are prohibited in competition and modafinil is on the World Anti-Doping Agency list, with the therapeutic-use exemption process drawing an operational line between treatment and enhancement; see Enhancement in sport and, for the anticipated genetic version, Gene doping. Military organisations have used modafinil and, historically, amphetamine for sustained operations, which is the clearest institutional endorsement of pharmacological cognitive enhancement anywhere and the setting in which that collective pressure is least deniable.

The wider context is set by Human enhancement and by the alternatives: Non-invasive neuromodulation devices marketed for cognition have their own replication problems, the psychedelic microdosing taken up under Psychedelic therapy reports benefits that self-blinded designs do not confirm, Intelligence amplification argues that external tools have delivered far more than any drug, and the genetic route described in Genetic enhancement of cognition is constrained by polygenicity. Interest has also moved toward compounds that target ageing biology on the hypothesis that preserving cognition is easier than augmenting it, a framing shared with Healthspan research and pursued in Exercise as a geroprotector, which remains the best-evidenced intervention for cognitive function across the lifespan.

§Open questions

No nootropic has been shown to improve a real-world outcome — a grade, a diagnosis rate, a piece of work — in a controlled trial in healthy adults. Laboratory tasks are the entire evidence base, and their relation to consequential performance is weak. Long-term safety in non-patients is similarly unstudied: the trials that exist run for weeks, and the use pattern that matters runs for years.

Whether any pharmacological agent can raise cognitive capacity, as opposed to shifting arousal along a curve the brain already occupies, is the question Giurgea posed and it remains open. Sixty years after piracetam, no compound has clearly answered it in the affirmative.

§See also

• Human enhancement
• Intelligence amplification
• Non-invasive neuromodulation
• Enhancement in sport
• Genetic enhancement of cognition
• Bioethics of enhancement
• Biohacking and grinders
• Engineered sleep reduction

§References